Skip to main content
Translational Respiratory Medicine

Table 1 First line trials of 1 st generation TKI in EGFR mutated patients

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

Study

N

OR%

mPFS (mo)

mOS (mo)

First Signal 4

    

Gefitinib

26

85

8

27.2

Cis/Gem

16

38

2.1

25.6

IPASS 5

    

Gefitinib

132

71

9.5

19

Carbo/Taxol

129

47

6.5

18

WJTOG 6

    

Gefitinib

86

62

9.2

30.9

Cis/Doce

86

31

6.3

NR

NEJOG 7

    

Gefitinib

114

74

10.8

27.7

Carbo/Taxol

110

31

5.4

26.6

OPTIMAL 8

    

Erlotinib

83

83

13.1

NR

Carbo/Gem

72

36

4.6

NR

EURTAC 9

    

Erlotinib

86

58

9.7

NR

Plat Doublet

87

15

5.2

NR

  1. N, number of patients; OR, objective response rate; mPFS, median progression free servival; mOS, median overall survival; mo, months; cis, cisplatin; gem, gemcitabine; carbo, carboplatin; doce, docetaxel; plat, platinum; NR, not reached.
Back to article page